Global Pharmaceutical R&D Pipeline (Fourth-Quarter 2008) - Special Report - 2009/04/09 - Fitch Research

Report title: Global Pharmaceutical R&D Pipeline (Fourth-Quarter 2008)

from Fitch Research
29 page (19994 word) report published Apr 09, 2009

Price $275.00 available for immediate download

Report Overview

Search Inside

About Fitch Research

...Fitch Ratings' global pharmaceutical team is presenting its Global Pharmaceutical R&D Pipeline report for the fourth quarter of 2008. This report includes the most current, key late-stage research and development (R&D) brand-name pharmaceutical projects, as well as up-to-date financial measures that reflect the risks facing pharmaceutical developers. Recent market introductions of innovative and generic drug products are highlighted as well. The intent of the regular update is to keep investors informed of the dynamics of the brand name pharmaceutical portfolios of the major U.S. and European participants in the industry. Fitch issues this report on a quarterly basis following earnings reporting. Data Presentation...

Report Type:

Special Report

Company(ies):

Abbott Laboratories, Amgen, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Company, Inc., Novartis AG, Pfizer Inc., Roche Holding Ltd., Sanofi-Aventis S.A., Schering-Plough Corporation, Wyeth

Ticker(s):

ABT , AMGN , AZN , BAY , BMY , GSK , JNJ , LLY , MRK , NOVN , PFE , RO , SAN , SGP , WYE

Issuer:

Schering-Plough Corporation

Free Sample:

Click Here to Download

Format:

PDF

Enter the keyword(s) which you would like to search for within this document and click "Search"

Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.

Also from Fitch Research

Fitch: Bristol-Myers Squibb's Ratings Unlikely to be Affected by Mead Johnson Spin-off $85.00
Fitch Revises Eli Lilly & Co.'s Outlook to Negative $85.00
Fitch Downgrades Merck and Upgrades Schering-Plough to 'A+' Following Merger; Outlook Stable $85.00
GlaxoSmithKline PLC $165.00
Bayer AG $165.00
Fitch: European Pharma Faces Declining Profitability on Diversification Pressures $85.00
Novartis AG $165.00
Fitch: Pension Contributions Remain a Credit Concern for U.S. Corporate Issuers in 2009/10 $85.00

Price: $275.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.